Breast Cancer Clinical Trials | Breast Cancer Awareness Month

Advancing Breast Cancer Research Through Patient-Centric Clinical Trials

October 30, 2026

Breast cancer research has made considerable progress over the years, from improved diagnostic approaches to treatments designed around specific tumour characteristics. Clinical trials continue to play an important role in this progress, helping researchers evaluate new therapies, refine existing treatment approaches and better understand how breast cancer responds to treatment.

During Breast Cancer Awareness Month, it is worth looking beyond awareness alone and recognising the clinical research that contributes to better treatment options and improved patient outcomes.

At Lambda Therapeutic Research and Novum Pharmaceutical Research Services, we work with global pharmaceutical and biotechnology companies to conduct complex oncology clinical trials. Our experience in breast cancer studies, combined with integrated clinical research capabilities, supports the development of new treatment options for patients worldwide.

Breast Cancer: The Continuing Need for Research

Breast cancer remains one of the most significant global health challenges. According to the World Health Organization (WHO), an estimated 2.4 million women were diagnosed with breast cancer worldwide in 2024, resulting in approximately 694,000 deaths. At the end of 2024, around 8.2 million women were living with breast cancer.

Breast cancer was the most commonly diagnosed cancer among women in 164 of 186 countries in 2024, highlighting its significant global impact.

While advances in screening, diagnosis and treatment have improved outcomes in many parts of the world, significant differences remain in access to early diagnosis and quality cancer care. Survival outcomes continue to vary considerably between countries, partly due to differences in healthcare infrastructure, timely diagnosis and access to treatment.

Breast cancer is not a single disease. It comprises several subtypes with different biological characteristics, treatment responses and clinical outcomes. Factors such as hormone receptor status, HER2 expression and other molecular markers help determine appropriate treatment approaches.

This variation makes continued clinical research essential. Understanding how different patient populations respond to specific therapies helps researchers evaluate more targeted treatment strategies and identify approaches that may improve outcomes.

How Clinical Trials Are Shaping Breast Cancer Treatment

Clinical trials are essential to translating scientific discoveries into treatments that can be evaluated for use in clinical practice. In breast cancer, research increasingly focuses on understanding tumour biology and identifying treatments that address specific disease characteristics. Some important areas of ongoing research include:

Targeted Therapies and HER2-Positive Breast Cancer

HER2-positive breast cancer is characterised by HER2 protein overexpression and/or HER2 gene amplification. HER2 status is an important biomarker for determining treatment approaches. Targeted therapies such as trastuzumab and pertuzumab have significantly changed the treatment approach for this subtype.

Clinical research continues to evaluate new HER2-targeted agents, treatment combinations and antibody-drug conjugates (ADCs), with the aim of improving treatment response and addressing disease progression.

Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer (TNBC) is characterised by the absence of oestrogen receptor (ER) and progesterone receptor (PR) expression, along with the absence of HER2 overexpression or gene amplification. These characteristics limit the applicability of conventional endocrine and HER2-targeted therapies. Clinical trials are evaluating different approaches, including immunotherapy, antibody-drug conjugates and new chemotherapy combinations, to expand treatment options for patients with TNBC.

Immunotherapy and Combination Treatments

Immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, is an important area of breast cancer research. These treatments aim to help the immune system recognise and respond to cancer cells. Clinical trials are evaluating immunotherapy, alone or in combination with chemotherapy and other treatments, in selected patient populations, particularly in certain forms of triple-negative breast cancer.

Biomarker-Based and Personalised Treatment Approaches

Advances in molecular testing and biomarker identification are helping researchers better understand differences between breast cancer subtypes. Clinical trials increasingly use these findings to identify patient populations that may respond differently to specific treatments. This supports more targeted clinical development and helps evaluate treatment approaches based on individual tumour characteristics.

Together, these research areas reflect a shift towards more precise treatment strategies. Clinical trials remain central to evaluating their safety, efficacy and potential role in patient care.

Lambda’s Oncology Experience: Supporting Complex Clinical Trials

Conducting oncology clinical trials requires experience in patient recruitment, site management, protocol execution, safety monitoring and data management. These requirements become particularly important in studies involving advanced disease, complex treatment regimens and multiple clinical assessments. At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes 300+ clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.

85+

Oncology Trials

8,000+

Patients

1,000+

Global Sites

Lambda has established a solid track record in breast cancer clinical trials, conducting 25+ clinical trials in various indications. These include complex disease presentations such as metastatic and triple-negative breast cancer (TNBC). Our experience includes studies involving more than 2,000 patients, reflecting our ability to manage complex clinical programmes across multiple sites while maintaining quality, patient safety and data integrity.

Biologics and Biosimilar Experience in Oncology:

Biologics and biosimilars play an increasingly important role in oncology treatment, particularly in breast cancer, where HER2-targeted therapies have significantly changed treatment approaches.

Lambda Therapeutic Research has experience supporting clinical development programmes involving oncology biologics and biosimilar candidates, with particular experience in breast cancer studies involving trastuzumab and pertuzumab.

Our clinical research experience includes:

HER2-targeted therapies: Trastuzumab and pertuzumab, including combination studies, across metastatic and HER2-positive breast cancer indications.
Antibody-drug conjugates (ADCs): Trastuzumab emtansine in advanced and metastatic breast cancer.

Beyond breast cancer, our oncology portfolio also includes clinical studies involving biologics such as denosumab, bevacizumab, pembrolizumab, rituximab, nivolumab and other targeted therapies across multiple cancer indications.

Integrated Clinical Research Capabilities

At Lambda, our integrated service capabilities support different stages and operational requirements of clinical development.

Clinical Operations: Study planning, site management, patient recruitment and clinical trial execution.
Medical Imaging: Imaging assessments and centralised imaging support for oncology studies.
Pharmacovigilance: Safety case processing, medical review and ongoing safety surveillance.
Biostatistics and Data Management: Statistical planning, clinical data management and analysis.
Medical and Scientific Writing: Clinical study documentation and regulatory writing.
Bioanalytical Services: Analytical support for clinical development programmes, as required by study design.

By bringing these capabilities together, we support sponsors in managing the operational and scientific requirements of complex oncology programmes.

Our experience supporting regulatory submissions to the US FDA, EMA and ANVISA reflects our understanding of global regulatory requirements and clinical development processes.

Supporting Breast Cancer Clinical Trials with Integrated Expertise

Breast cancer clinical trials often involve complex eligibility criteria, biomarker-based patient selection, specialised assessments and multiple treatment cycles. Successful execution requires careful planning, experienced clinical teams and coordination across study sites. At Lambda Therapeutic Research, our experience in oncology clinical research supports sponsors in managing these requirements through:

Strategic Site Selection and Feasibility

We assess site capabilities, investigator experience, patient availability and access to relevant oncology populations to identify suitable sites for breast cancer studies. This helps establish a strong foundation for patient recruitment and study execution.

Patient Recruitment and Retention

Recruiting eligible patients can be challenging, particularly in studies involving specific biomarkers, disease stages or previous treatment requirements. Our clinical operations teams work closely with investigators and sites to support patient identification, recruitment and retention throughout the study.

Clinical Trial and Protocol Management

Breast cancer studies may involve multiple treatment cycles, biomarker assessments, imaging procedures and laboratory evaluations. Our clinical teams coordinate study activities, monitor protocol compliance and maintain oversight of timelines and data collection across participating sites.

Patient Safety and Data Quality

Ongoing safety monitoring, timely adverse event reporting and accurate clinical documentation are essential in oncology trials. Our integrated pharmacovigilance, biostatistics and data management capabilities support safety oversight and the collection of reliable clinical data.

Through this integrated approach, Lambda supports the operational and scientific requirements of breast cancer clinical trials, helping sponsors manage complex studies across different stages of clinical development.

About Lambda

Lambda & Novum deliver comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.

Lambda Therapeutic Research has received several industry recognitions, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ recognition from UBS Transformance. The company also received the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilars Awards 2023.

“Planning an oncology clinical trial? Connect with Lambda and Novum to discuss your clinical development requirements. Get in touch with our team of experts.